Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma
Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.
“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”
“The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, Ph.D. “Denali was founded by a group of U.S.-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”
Resolian (formerly Alliance Pharma Inc. and Drug Development Solutions Ltd.) is a leading global research laboratory that provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. Over 500 experts across the U.S., U.K., China, and Australia deliver quality results, ensuring the highest standard of regulatory compliance throughout the drug development continuum. Resolian’s dedicated laboratories are equipped with state-of-the-art technology that meet the needs of preclinical and clinical programs at any scale.
About Denali Medpharma
Denali is a China based bioanalytical CRO, now part of Resolian Bioanalytics. With 70 full-time employees, its core leadership have extensive working experience in the U.S. and China CRO industry. It is equipped with the world’s most advanced instruments. Denali’s quality assurance system is established in strict accordance with domestic and foreign laws and regulations related to bioanalysis. Denali is well known as the industry leader in China in the bioanalysis of oligonucleotide drugs and mRNA vaccines (PK/PD and ADA), liposomal drug (free and encapsulated drug), ultra-sensitive assays for inhalation drugs, and biomarker assays, etc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
V-Nova completes the acquisition of Parallaxter Srl, the company behind the PresenZ XR technology29.11.2023 10:00:00 CET | Press release
V-Nova, a leading provider of data compression solutions, announces the full acquisition of Parallaxter Srl, completing its prior investments in the company and incorporating it into the V-Nova group. Parallaxter are the XR experts behind the PresenZ technology and this acquisition will greatly expand V-Nova’s portfolio of IP and technologies in VR/XR and gaming, as well as further strengthen its position in the data and video compression industry. V-Nova PresenZ, a Lumiere Award winning format that combines Parallaxter's PresenZ technology and V-Nova's point-cloud compression, is set to revolutionize storytelling in VR. It offers users cinematic photorealism and 6DoF for real-time navigation in pre-rendered scenes, breaking free from static viewpoints and ensuring full immersiveness. V-Nova PresenZ is distributed at scale also to stand-alone XR devices thanks to MPEG-5 LCEVC enhanced pixel streaming. The format dovetails with standard Computer Graphics and Special FX production workfl
PUMA RE:SUEDE Pilot Project Turns Experimental Sneakers Into Compost29.11.2023 09:29:00 CET | Press release
Sports company PUMA showed that it can successfully turn an experimental version of its classic SUEDE sneaker into compost under certain tailor-made industrial conditions, as it announced the results of its two-year-long RE:SUEDE experiment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129456533/en/ Sports company PUMA showed that it can successfully turn an experimental version of its classic SUEDE sneaker into compost under certain tailor-made industrial conditions, as it announced the results of its two year-long RE:SUEDE experiment. (Photo: Business Wire) In 2021, PUMA created 500 pairs of the experimental RE:SUEDE, using Zeology tanned suede, a TPE outsole and hemp fibres. The RE:SUEDEs were worn for half a year by volunteers in Germany to test the comfort and durability of the shoes before PUMA sent them to a specially equipped industrial composting area operated by its partner Ortessa Group in the Netherlands. A
Matmut Selects Earnix to Deliver Comprehensive Modeling, Pricing, and Rating Engine29.11.2023 09:00:00 CET | Press release
Earnix, the global provider of AI-based SaaS solutions for insurers and banks, today announced that Matmut, a major mutual insurer in France, has chosen, and is now working with, Earnix as its partner. Matmut is one of France's leading property and casualty insurers, offering a range of personal and commercial insurance products. Earnix solutions address Matmut's business and IT needs by integrating easily into its tech stack, enabling rapid pricing adjustments. With Earnix, Matmut can seamlessly integrate machine learning models as part of its pricing strategy. This enables Matmut to not only build, test, and deploy rates into the market with ease, but also benefit from automation, governance, and auditability. Emeric Bellanger, Technical Director of Claims and Pricing at Matmut said, “This partnership empowers our pricing team to provide top leaders with recommended pricing changes based on simulation and the ability to implement these changes more easily." Earnix solutions enable ne
Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP2829.11.2023 08:00:00 CET | Press release
To accelerate the transition to net zero health systems, global healthcare leaders from the Sustainable Markets Initiative Health Systems Task Force are in advanced discussions with energy providers in China and India to scale renewable power across their supply chains. This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries. China and India are key markets for pharmaceuticals manufacturing, estimated to account for up to 50% of materials for medicines.i This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123104876/en/ Air pollution over Shanghai illustrating the climate health crisis. (Photo: Business Wire) In China, the power agreements would unlock renewable energy in Jiangsu, Guangdong, Shanghai and Beijing. The agreements are set to bring around 70 megawatts (MW) of renewable power a
Capcom Reveals Dragon’s Dogma 2 Scheduled to Launch March 22, 2024!29.11.2023 02:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2, the latest game in the Dragon’s Dogma series, is scheduled to be released on March 22, 2024. With the launch of Dragon’s Dogma 2, Capcom closes out a stellar year of major title releases for its 2023 fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128898951/en/ Dragon's Dogma 2 is a single player, narrative driven action-RPG and the latest title in the Dragon’s Dogma series. The game features intricately crafted, gorgeous visuals powered by Capcom’s proprietary RE ENGINE that elevate its unique gameplay experience to provide a truly immersive fantasy world sure to delight both newcomers as well as long-time fans of the series. (Graphic: Business Wire) Dragon’s Dogma 2 is the latest title in the series, and the first mainline entry since the original Dragon’s Dogma was released in 2012. The game is being developed on Capcom’s proprietary RE EN